Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030962 · ClinicalTrials.gov registry record · Phase 1
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 292
- Enrollment target
NCT04030962 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 292 participants.
The verdict
NCT04030962, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 292 participants
- Enrollment target
Study Summary
This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 began. Stage 2 also evaluated the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease (DED), and assessed the plasma and tear exposure of both ophthalmic solutions.
Interventions
- DRUG Lifitegrast 5% Ophthalmic Solution
- DRUG AGN-242428
- DRUG AGN-231868
- OTHER AGN-242428 Vehicle
- OTHER AGN-231868 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2022-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04030962
The ClinicalTrials.gov registry entry for NCT04030962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lifitegrast 5% Ophthalmic Solution is the first listed.
NCT04030962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04030962 about?
NCT04030962 is a clinical study titled "A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease". This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 began. Stage ...
What is the current status of trial NCT04030962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 292 participants. The study started on 2020-03-04. Estimated completion is 2022-03-18.
What interventions are being tested in trial NCT04030962?
The interventions under investigation include: Lifitegrast 5% Ophthalmic Solution (DRUG), AGN-242428 (DRUG), AGN-231868 (DRUG), AGN-242428 Vehicle (OTHER), AGN-231868 Vehicle (OTHER).
Who is sponsoring clinical trial NCT04030962?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.